Related Experiment Videos
Inhibiting tissue invasion and metastasis as targets for cancer therapy
1Department of Nuclear Medicine, St. Vincent's Hospital, Dublin, Ireland.
Abstract:
Many of the steps involved in cancer spread are potential targets for anti-metastatic treatment. Until recently, research aimed at inhibiting metastasis has concentrated on the proteases, especially on urokinase-type plasminogen activator and collagenase IV. However, recent data suggests that both adhesion proteins and motility factors could also serve as targets for new treatments to prevent cancer invasion and metastasis. Almost all the work to date using anti-metastatic agents has been carried out using either in vitro artificial membranes or with animal models. It is, however, likely that some of the inhibitors of experimental metastasis which are described will be evaluated in clinical trials in the near future.
Insights
New anti-metastatic treatments targeting cancer spread are emerging. Research is expanding beyond proteases to include adhesion proteins and motility factors for inhibiting cancer invasion and metastasis.
Area of Science:
- Oncology
- Cancer Metastasis Research
Background:
- Cancer metastasis involves multiple steps, offering various targets for therapeutic intervention.
- Historically, research focused on inhibiting proteases like urokinase-type plasminogen activator and collagenase IV.
- Emerging research highlights adhesion proteins and motility factors as potential anti-metastatic targets.
Purpose of the Study:
- To review and highlight potential therapeutic targets for inhibiting cancer invasion and metastasis.
- To discuss the shift in focus from proteases to adhesion proteins and motility factors.
- To provide an outlook on the clinical translation of experimental anti-metastatic agents.
Main Methods:
- Review of existing literature on cancer metastasis and anti-metastatic agents.
- Analysis of research trends focusing on therapeutic targets.
- Evaluation of experimental models used in anti-metastasis research.
Main Results:
- Proteases, adhesion proteins, and motility factors are identified as key targets in cancer spread.
- In vitro and animal models are primary tools for evaluating anti-metastatic agents.
- Several experimental metastasis inhibitors show promise for future clinical trials.
Conclusions:
- Targeting cancer spread through novel anti-metastatic agents is a promising therapeutic strategy.
- The scope of therapeutic targets is broadening to include adhesion proteins and motility factors.
- Clinical trials are anticipated for promising experimental anti-metastatic therapies.